Last reviewed · How we verify

NCT06133660

Influence of Intravitreal Aqueous Tamponade on Lens Status and Ocular

Completed Last updated 15 November 2023
What this trial tests

trial testing pars plana vitrectomy in Aqueous Tamponade in 21 participants. Completed in 1 March 2023.

Timeline
30 October 2020
Primary endpoint
1 October 2022
1 March 2023

Quick facts

Lead sponsorBo Jia
StatusCompleted
Study typeOBSERVATIONAL
Enrollment21
Start date30 October 2020
Primary completion1 October 2022
Estimated completion1 March 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Bo Jia

Who can join

Adults 16 to 65, any sex, with Aqueous Tamponade or Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To observe the effects of vitreous cavity Balanced salt solution (BSS) tamponade on the state of the lens and related parameters of the eye, and whether the changes of the above parameters are correlated with age, gender, diabetes or not, etc., so as to provide references for the diagnosis and treatment of related diseases and scientific research.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of pars plana vitrectomy

Trials testing the same drug.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06133660.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing